Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference

Rhea-AI Summary

Delcath Systems, traded as DCTH, will participate in the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 3:00 PM ET. The event will feature a fireside chat and management will engage in virtual one-on-one meetings. Delcath focuses on treating liver cancers using its proprietary percutaneous hepatic perfusion (PHP) system, currently under development in the U.S. as HEPZATO KIT for metastatic ocular melanoma. In Europe, the PHP system is approved as CHEMOSAT to treat various liver cancers.

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Horizons in Oncology Conference:

• Date: April 14, 2022 at 3:00 PM ET
• Format: Fireside Chat
• Webcast link: https://wsw.com/webcast/canaccord74/dcth/2433851
  

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your conference representative or James@HaydenIR.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is the date and time of Delcath Systems' participation in the Canaccord Genuity Conference?

Delcath Systems will participate in the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 3:00 PM ET.

What format will Delcath Systems' presentation at the conference be?

Delcath Systems' presentation will be in the format of a fireside chat.

How can I attend Delcath Systems' conference discussion?

You can access Delcath Systems' conference discussion through the webcast link: https://wsw.com/webcast/canaccord74/dcth/2433851.

What is the purpose of Delcath Systems' proprietary PHP system?

The PHP system is designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure and side effects.

Under what names is Delcath's PHP system known in the U.S. and Europe?

In the U.S., the PHP system is known as the HEPZATO KIT, while in Europe, it is referred to as CHEMOSAT.